DURHAM, N.C. & SEATTLE--January 12, 2025--Leading epigenome editing company Tune Therapeutics (Tune) today announced the completion of over $175M in financing led by New Enterprise Associates, Yosemite, Regeneron Ventures and...
TyRx enrolls first patient in CITADEL study for AIGISRx™ anti-bacterial envelope with ICD replacements
News | 03. 24. 2010
TYRX
MONMOUTH JUNCTION, N.J., March 24, 2010--(EON: Enhanced Online News) - TYRX, Inc., a leader in the commercialization of implantable medical devices designed to help reduce infection, announced today that it has begun enrollment in CITADEL, the second of two large scale, prospective, multicenter studies.
